SCHEDULE: Utmost Group's Stake in TriSalus Life Sciences Diluted

Sentiment:

Beneficial Ownership Report


Utmost Group PLC's beneficial ownership in TriSalus Life Sciences Inc. has decreased to 0.0529% due to an increase in the issuer's outstanding shares.

Capital raiseThe number of outstanding shares of TriSalus Life Sciences Inc. has increased to 37,838,962, which often results from a capital raise or other dilutive corporate actions.
Worse than expectedUtmost Group PLC's percentage of beneficial ownership in TriSalus Life Sciences Inc. decreased from an unspecified prior level to 0.0529% due to an increase in the issuer's total outstanding shares, indicating dilution of their stake.

Summary

  • Utmost Group PLC, a United Kingdom-based entity, reported beneficial ownership of 2,000,588 shares of TriSalus Life Sciences Inc. Common Stock.
  • This represents 0.0529% of TriSalus Life Sciences Inc.'s outstanding common stock.
  • The percentage of ownership decreased because the total number of outstanding shares of TriSalus Life Sciences Inc. increased to 37,838,962.
  • Utmost Group PLC holds sole voting and dispositive power over all 2,000,588 shares.
  • Lombard International Assurance SA, a subsidiary acquired by Utmost Group on December 30, 2024, is identified as the entity that acquired the securities.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership. The decrease in percentage ownership for the reporting entity is a neutral-to-slightly-negative fact for their stake, but the filing provides no information to assess the overall sentiment for the issuer.

Negatives

  • Utmost Group PLC's percentage of beneficial ownership in TriSalus Life Sciences Inc. has decreased to 0.0529% from a previously higher, unspecified percentage, due to share dilution.

Risks

  • The increase in TriSalus Life Sciences Inc.'s outstanding shares could lead to further dilution for existing shareholders if not accompanied by proportional growth in company value.

Future Outlook

No forward-looking statements or guidance regarding TriSalus Life Sciences Inc.'s future performance or strategic direction are provided in this ownership disclosure.

Management Comments

  • Ian Maidens, Group CFO of Utmost Group PLC, certified that the information set forth in the statement is true, complete, and correct to the best of his knowledge and belief.

Industry Context

This filing is a routine disclosure of beneficial ownership, indicating a passive investment stake by an institutional investor. The decrease in percentage ownership due to an increased share count is a common occurrence in the market, often resulting from capital raises or other corporate actions by the issuer.

Stakeholder Impact

  • Existing shareholders of TriSalus Life Sciences Inc. may experience dilution of their ownership percentage due to the increase in the total number of outstanding shares.

Key Dates

DateDescription
2024-12-30Utmost Group acquired Lombard International Assurance SA.
2025-05-19Date of event which required the filing of this statement.
2025-08-11Signature date of the filing by Ian Maidens, Group CFO of Utmost Group PLC.

Keywords

TriSalus Life Sciences, Utmost Group, Schedule 13G, Beneficial Ownership, Common Stock, Share Dilution, SEC Filing, Institutional Investor

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.